AcelRx Pharmaceuticals Analyst Ratings
AcelRx Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 632.76% | Alliance Global Partners | → $4.25 | Initiates Coverage On | → Buy |
| 09/25/2023 | 762.07% | HC Wainwright & Co. | $8 → $5 | Maintains | Buy |
| 08/18/2023 | 1279.31% | HC Wainwright & Co. | → $8 | Upgrades | Neutral → Buy |
| 03/14/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 08/17/2021 | 762.07% | HC Wainwright & Co. | $7 → $5 | Maintains | Buy |
| 08/13/2020 | 44.83% | Credit Suisse | $0.69 → $0.84 | Maintains | Underperform |
| 07/20/2020 | 18.97% | Credit Suisse | $1 → $0.69 | Downgrades | Neutral → Underperform |
| 03/17/2020 | 1106.9% | HC Wainwright & Co. | $9 → $7 | Maintains | Buy |
| 11/11/2019 | 244.83% | Credit Suisse | $7 → $2 | Downgrades | Outperform → Neutral |
| 08/05/2019 | 1106.9% | Credit Suisse | → $7 | Assumes | → Outperform |
| 07/10/2019 | — | Credit Suisse | Assumes | → Outperform | |
| 04/24/2019 | — | B. Riley Securities | Initiates Coverage On | → Buy | |
| 02/15/2019 | 1106.9% | Credit Suisse | → $7 | Initiates Coverage On | → Outperform |
| 10/23/2018 | 1451.72% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 10/15/2018 | 1279.31% | Jefferies | → $8 | Upgrades | Hold → Buy |
| 10/10/2018 | 1624.14% | Ladenburg Thalmann | $7 → $10 | Reiterates | Buy → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/02/2023 | 632.76% | 聯盟全球合作夥伴 | →$4.25 | 開始承保 | →購買 |
| 09/25/2023 | 762.07% | HC Wainwright公司 | $8→$5 | 維護 | 買 |
| 2023年08月18日 | 1279.31% | HC Wainwright公司 | →$8 | 升級 | 中性→購買 |
| 03/14/2022 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 2021/08/17 | 762.07% | HC Wainwright公司 | $7→$5 | 維護 | 買 |
| 2020年08月13日 | 44.83% | 瑞士信貸 | $0.69→$0.84 | 維護 | 表現不佳 |
| 07/20/2020 | 18.97% | 瑞士信貸 | $1→$0.69 | 評級下調 | 中性→表現不佳 |
| 03/17/2020 | 1106.9% | HC Wainwright公司 | $9→$7 | 維護 | 買 |
| 2019年11月11日 | 244.83% | 瑞士信貸 | $7→$2 | 評級下調 | 跑贏→中性 |
| 2019年08月05日 | 1106.9% | 瑞士信貸 | →$7 | 假設 | →跑贏大盤 |
| 2019年07月10日 | - | 瑞士信貸 | 假設 | →跑贏大盤 | |
| 2019年04月24日 | - | B.萊利證券 | 開始承保 | →購買 | |
| 2019年02月15日 | 1106.9% | 瑞士信貸 | →$7 | 開始承保 | →跑贏大盤 |
| 2018年10月23日 | 1451.72% | B.萊利證券 | →$9 | 開始承保 | →購買 |
| 2018年10月15日 | 1279.31% | 傑富瑞 | →$8 | 升級 | 持有→購買 |
| 2018年10月10日 | 1624.14% | 拉登堡·塔爾曼 | $7→$10 | 重申 | 購買→購買 |
What is the target price for AcelRx Pharmaceuticals (ACRX)?
AcelRx製藥公司(ACRX)的目標價是多少？
The latest price target for AcelRx Pharmaceuticals (NASDAQ: ACRX) was reported by Alliance Global Partners on October 2, 2023. The analyst firm set a price target for $4.25 expecting ACRX to rise to within 12 months (a possible 632.76% upside). 3 analyst firms have reported ratings in the last year.
聯盟全球合作夥伴於2023年10月2日報道了AcelRx製藥(納斯達克：ACRX)的最新目標價。這家分析公司將目標價定為4.25美元，預計ACRX將在12個月內上漲至(可能上漲632.76)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for AcelRx Pharmaceuticals (ACRX)?
AcelRx製藥公司(ACRX)的最新分析師評級是多少？
The latest analyst rating for AcelRx Pharmaceuticals (NASDAQ: ACRX) was provided by Alliance Global Partners, and AcelRx Pharmaceuticals initiated their buy rating.
聯盟全球夥伴公司提供了對AcelRx製藥公司(納斯達克代碼：ACRX)的最新分析師評級，AcelRx製藥公司啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for AcelRx Pharmaceuticals (ACRX)?
AcelRx製藥(ACRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AcelRx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AcelRx Pharmaceuticals was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與AcelRx製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。AcelRx製藥的上一次評級是在2023年10月2日提交的，所以你應該預計下一次評級將在2024年10月2日左右的某個時候公佈。
Is the Analyst Rating AcelRx Pharmaceuticals (ACRX) correct?
分析師對AcelRx製藥公司(ACRX)的評級正確嗎？
While ratings are subjective and will change, the latest AcelRx Pharmaceuticals (ACRX) rating was a initiated with a price target of $0.00 to $4.25. The current price AcelRx Pharmaceuticals (ACRX) is trading at is $0.58, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的AcelRx製藥(ACRX)評級是以0.00美元至4.25美元的目標價啟動的。AcelRx製藥公司(AcelRx PharmPharmticals)目前的交易價格為0.58美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。